<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04600115</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 94980</org_study_id>
    <secondary_id>R01HL135328</secondary_id>
    <nct_id>NCT04600115</nct_id>
  </id_info>
  <brief_title>New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)</brief_title>
  <official_title>New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study's main specific aims are;&#xD;
&#xD;
        1. To develop robust acquisition and reconstruction methods specifically for the study of&#xD;
           microvascular cardiac remodeling with MRI which will include very innovative&#xD;
           quantitative perfusion methods, as well as fibrosis quantification, longitudinal strain,&#xD;
           and phase contrast imaging for flow.&#xD;
&#xD;
        2. Test the new methods for identifying the clinical task of characterizing HFpEF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure with preserved ejection fraction (HFpEF) is currently being studied intensely&#xD;
      as several large trials of drug therapies have failed to benefit patients. Better&#xD;
      characterization of these patients is important, and there are open questions regarding&#xD;
      microvascular disease and remodeling in the HFpEF population. New MRI methods could be ideal&#xD;
      to better characterize and understand HFpEF and its response to treatments. This project&#xD;
      seeks to develop, evaluate and apply new MRI methods for high-end perfusion imaging. These&#xD;
      methods will estimate endo/epi ratios across the cardiac cycle in free-breathing studies,&#xD;
      which will provide new information about microvascular disease. This is of particular value&#xD;
      for assessing HFpEF.&#xD;
&#xD;
      The idea of this project is to combine new techniques for quantitative cardiac perfusion MRI&#xD;
      imaging that would be ideally suited for answering open questions regarding HFpEF and for&#xD;
      studying microvascular disease. The methods could potentially also predict patients who might&#xD;
      respond to particular drug therapies.&#xD;
&#xD;
      The new techniques include &quot;simultaneous multi-slice&quot; imaging which has not been used this&#xD;
      way for myocardial perfusion imaging. In particular, we are developing an innovative hybrid&#xD;
      of the standard saturation pulse and steady state spoiled gradient echo acquisitions. We also&#xD;
      are developing a new method for using 3D &quot;stack of stars&quot; + 2D slice in the same scan for&#xD;
      arterial input function assessment to quantify perfusion, and new methods for measuring T1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2017</start_date>
  <completion_date type="Anticipated">March 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 3, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Image quality improvement</measure>
    <time_frame>Time in the scanner to be 60-90 minutes.</time_frame>
    <description>comparison of perfusion, myocardial perfusion reserve (MPR), function possibly including strain, and extracellular volume (ECV, from T1 mapping).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>MRI Scans</condition>
  <arm_group>
    <arm_group_label>MRI vs.PET with/without Cardiac disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adenosine Regadenoson O-15 Labeled radioactive water MRI PET Imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine</intervention_name>
    <description>Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion</description>
    <arm_group_label>MRI vs.PET with/without Cardiac disease</arm_group_label>
    <other_name>Adenoscan</other_name>
    <other_name>Adenocard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson</intervention_name>
    <description>0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.</description>
    <arm_group_label>MRI vs.PET with/without Cardiac disease</arm_group_label>
    <other_name>Lexiscan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>O-15 labeled radioactive water</intervention_name>
    <description>O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging</description>
    <arm_group_label>MRI vs.PET with/without Cardiac disease</arm_group_label>
    <other_name>O-15 water</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson</description>
    <arm_group_label>MRI vs.PET with/without Cardiac disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET Imaging</intervention_name>
    <description>Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day</description>
    <arm_group_label>MRI vs.PET with/without Cardiac disease</arm_group_label>
    <other_name>Positron Emission Tomography Imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All participants will be over the age of 18 and able to provide consent&#xD;
&#xD;
               -  Group A (volunteers, with or without cardiac disease): Volunteers will be&#xD;
                  available for at least one study visit&#xD;
&#xD;
               -  Group B (HFpEF patient volunteers): Volunteers will have a diagnosis of HFpEF and&#xD;
                  be safe to be imaged with MRI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  minors&#xD;
&#xD;
          -  Critically ill patients, patients on ventilators, patients with unstable angina or&#xD;
             with hypotension, asthmatics, and other patients whose medical care or safety may be&#xD;
             at risk from undergoing an MRI examination will be excluded.&#xD;
&#xD;
          -  Patients with claustrophobia will also be excluded from the study if this cannot be&#xD;
             controlled with standard methods (valium or benadryl).&#xD;
&#xD;
          -  Patients with contraindication to MRI (metal implants, or certain types of heart&#xD;
             valves),&#xD;
&#xD;
          -  pregnant patients, , mentally disabled patients and prisoners will be excluded from&#xD;
             this study. (All criteria apply to patients and normal volunteers).&#xD;
&#xD;
          -  Gadolinium nephrotoxicity will be addressed by having patients with abnormal kidney&#xD;
             function (GFR&lt;30) excluded from the study due to the (very small) risk associated with&#xD;
             gadolinium contrast agents.&#xD;
&#xD;
          -  This threshold may be modified, depending on practices determined by the Radiology&#xD;
             Department and the IRB.&#xD;
&#xD;
          -  Patients with a known allergy or contraindication to Adenosine and/or Regadenoson will&#xD;
             be excluded from stress MRI cohorts.&#xD;
&#xD;
          -  All participants that will receive a stress agent will refrain from consuming caffeine&#xD;
             for at least 12 hours prior to each MRI&#xD;
&#xD;
          -  Subjects with a known contraindication to Adenosine and/or Regadenoson will only be&#xD;
             enrolled in scans where no stress agent will be administered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward DiBella, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nousheen Alasti, BS</last_name>
    <phone>801-585-6142</phone>
    <email>Nousheen.alasti@hsc.utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Collin Arsenault, BS.</last_name>
    <phone>801-587-8638</phone>
    <email>collin.arsenault@hsc.utah.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>university of Utah, Radiology Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nousheen Alasrti, BS</last_name>
      <phone>801-585-6142</phone>
      <email>Nousheen.Alasti@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Collin Arsenault, BS</last_name>
      <phone>801-587-8638</phone>
      <email>Collin.arsenault@hsc.utah.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>October 21, 2020</last_update_submitted>
  <last_update_submitted_qc>October 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Edward DiBella</investigator_full_name>
    <investigator_title>Ph.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
    <mesh_term>Regadenoson</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

